TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8881132

Group type: EXPERIMENTAL
Intervention: Fixed dose of nadroparin calcium (7500 anti-Xa IC units)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Variable dose of nadroparin calcium (100 to 150 anti-Xa IC units/kg)
Number of subjects: 283
Study: 1576050

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (300 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (600 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (1200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3831331

Group type: EXPERIMENTAL
Intervention: Cooperative learning situation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individualistic learning situation
Number of subjects: 48
Study: 3534632

Group type: EXPERIMENTAL
Intervention: 2‐alpha‐TPG-fenoterol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo-fenoterol
Number of subjects: 26
Study: 29221945

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 28127561

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional immunosuppressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 0
Study: 26193492

Group type: EXPERIMENTAL
Intervention: Computer-aided interlimb force coupling training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 23023231

Group type: EXPERIMENTAL
Intervention: Standard dose plain radiography
Number of subjects: 323

Group type: COMPARATOR
Intervention: 50% reduced dose plain radiography
Number of subjects: 323
Study: 20199208

Group type: EXPERIMENTAL
Intervention: Levodopa and complementary scalp electro-acupuncture
Number of subjects: 10

Group type: COMPARATOR
Intervention: Levodopa alone (control)
Number of subjects: 10
Study: 18312042

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (18 mg to 54 mg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 145
Study: 17134517

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) program, three times per week for 10 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Brief advice control group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) program
Number of subjects: 32
Study: 12940195

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 8113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8113
Study: 10863677

Group type: EXPERIMENTAL
Intervention: Short bouts of walking (10-15 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recovery from walking (10-15 minutes)
Number of subjects: 0
Study: 9333057

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin 500 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous levofloxacin 500 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin formulations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous levofloxacin infusion
Number of subjects: 40
Study: 8471403

Group type: EXPERIMENTAL
Intervention: Fengabine 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fengabine 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study: 3836854

Group type: EXPERIMENTAL
Intervention: 40 749 RP (2 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29220295

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 given once a week
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 given once every 3 weeks
Number of subjects: 300
Study: 27576882

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site surgery (LESS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional laparoscopic (CL) surgery
Number of subjects: 20
Study: 25034805

Group type: EXPERIMENTAL
Intervention: Shaded white tea
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ordinary green tea (Sagara)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Warm water
Number of subjects: 18
Study: 22695039

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius Ls‐33 (10 CFU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19477881

Group type: EXPERIMENTAL
Intervention: Nicotine (Nicorette 2 mg)
Number of subjects: 9
Study: 18705297

Group type: EXPERIMENTAL
Intervention: Mesalazine 800mg/daily (group M1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mesalazine 1.6gr 10 days/month (group M2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mesalazine 800mg/daily + Lactobacillus casei DG 16 billion/day for 10 days/month (group LM1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mesalazine 1.6gr + Lactobacillus casei DG 16 billion/day for 10 days/month (group LM2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG 16 billion/day for 10 days/month (group L)
Number of subjects: 75
Study: 16170253

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (AMH)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 27
Study: 12538221

Group type: EXPERIMENTAL
Intervention: 6% hetastarch in saline (HS‐NS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 6% hetastarch in balanced salt (HS‐BS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 90
Study: 11151579

Group type: EXPERIMENTAL
Intervention: 2‐stage endosseous root‐form implants (3 different implant systems)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) values
Number of subjects: 89
Study: 9019576

Group type: EXPERIMENTAL
Intervention: Axial and paraaxial fluorophotometry during acute phase of optic neuropathies
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Axial and paraaxial fluorophotometry during late phase of optic neuropathies
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy eyes)
Number of subjects: 21
Study: 1290315

Group type: EXPERIMENTAL
Intervention: Prudent diet plus at least 400 g/day of fruits and vegetables rich in dietary fibre and antioxidants, followed by moderate exercise (brisk walking and spot running) for 20 weeks after an initial 4-week diet period.
Number of subjects: 463

Group type: COMPARATOR
Intervention: Prudent diet only for 4 weeks, followed by no exercise for 20 weeks.
Number of subjects: 463
Study: 6363395

Group type: EXPERIMENTAL
Intervention: Rapid intramuscular neuroleptization at 10 mg per dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rapid intramuscular neuroleptization at 2 mg per dose
Number of subjects: 20
Study: 29898587

Group type: COMPARATOR
Intervention: BoNT‐A monotherapy (N=18)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BoNT‐A plus physical therapy (PT) (N=17)
Number of subjects: 35
Study: 28851729

Group type: EXPERIMENTAL
Intervention: iECG (AliveCor Kardia monitor)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: iECG
Number of subjects: 1001
Study: 26873817

Group type: EXPERIMENTAL
Intervention: Group 2 (greater patient involvement and information on individual fracture risk)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Group 1 (standard clinical practice)
Number of subjects: 816
Study: 25079942

Group type: EXPERIMENTAL
Intervention: Enhanced supervision (quarterly skills-based supervision by a district eye coordinator)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Routine supervision (existing supervision practices)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Enhanced supervision
Number of subjects: 343

Group type: COMPARATOR
Intervention: Routine supervision
Number of subjects: 343
Study: 22476378

Group type: EXPERIMENTAL
Intervention: Active exercise training during pregnancy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Non-exercising low-risk women
Number of subjects: 118
Study: 19576299

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) delivered via video teleconferencing (VTC)
Number of subjects: 126

Group type: COMPARATOR
Intervention: In-person control condition
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cost analysis of VTC and in-person modalities
Number of subjects: 126
Study: 17496732

Group type: EXPERIMENTAL
Intervention: Chromium picolinate and biotin (CPB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15246905

Group type: EXPERIMENTAL
Intervention: Once daily oral nitrates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice daily oral nitrates
Number of subjects: 0
Study: 11412645

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIP-TAZ)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IMI)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both groups (PIP-TAZ and IMI)
Number of subjects: 137
Study: 9756226

Group type: EXPERIMENTAL
Intervention: Specific information pamphlet and a general preoperative counselling video
Number of subjects: 30

Group type: COMPARATOR
Intervention: Video alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 7882263

Group type: EXPERIMENTAL
Intervention: Collaborative discharge planning (CNS and social worker)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard discharge planning (Control group not explicitly mentioned)
Number of subjects: 64
Study: 3204250

Group type: EXPERIMENTAL
Intervention: Aminophylline (theophylline) administered via constant intravenous infusion at mean levels of 15 +/- 2 mg/L SD
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29429134

Group type: EXPERIMENTAL
Intervention: Building on Family Strengths Program
Number of subjects: 110
Study: 28118695

Group type: EXPERIMENTAL
Intervention: Arm sling
Number of subjects: 57

Group type: COMPARATOR
Intervention: No arm sling
Number of subjects: 57
Study: 24633212

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study: 24602137

Group type: EXPERIMENTAL
Intervention: HM30181 (15, 60, or 180 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Loperamide alone
Number of subjects: 18
Study: 22956397

Group type: EXPERIMENTAL
Intervention: One-session motivational interviewing (MI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Four-session motivational interviewing (MI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 100
Study: 19954057

Group type: EXPERIMENTAL
Intervention: Stable plaque group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vulnerable plaque group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17889463

Group type: EXPERIMENTAL
Intervention: 1mg estradiol valerate/2mg dienogest (1EV/2DNG)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 15351191

Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Open AAA repair
Number of subjects: 1082
Study: 11316916

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 0
Study: 9875727

Group type: EXPERIMENTAL
Intervention: Focal lesions of the lateral cerebellar cortex and nuclei
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lesions of the mesial cerebellum and vermis
Number of subjects: 0
Study: 9197805

Group type: EXPERIMENTAL
Intervention: Condom motivation education class
Number of subjects: 205

Group type: COMPARATOR
Intervention: Treatment for STD (Comparison Group)
Number of subjects: 205
Study: 2293320

Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mequitazine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 29
Study: 6118215

Group type: EXPERIMENTAL
Intervention: Acebutolol (200 to 600 mg twice daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 15
Study: 31686094

Group type: EXPERIMENTAL
Intervention: Active treatment (LipiDiDiet product)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 278
Study: 26732026

Group type: EXPERIMENTAL
Intervention: Probiotic group consuming fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp lactis BB-12 (109 colony-forming units/d each) for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group consuming conventional fermented milk for 6 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 50
Study: 25980900

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 1663

Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 1663

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 1663
Study: 25951165

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g in 1000 mL of 0.9% saline solution infused over 24 hours for each of the 3 preoperative days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (1000 mL of 0.9% saline solution for the same time period)
Number of subjects: 60
Study: 22770431

Group type: EXPERIMENTAL
Intervention: Conventional bleaching technique with 38% hydrogen peroxide gel for one hour
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sealed bleaching technique with 38% hydrogen peroxide gel for one hour
Number of subjects: 80
Study: 21807566

Group type: EXPERIMENTAL
Intervention: BTDS 20
Number of subjects: 660

Group type: COMPARATOR
Intervention: BTDS 5
Number of subjects: 660

Group type: COMPARATOR
Intervention: Oxycodone 40 mg/day
Number of subjects: 660
Study: 18586992

Group type: EXPERIMENTAL
Intervention: Intensive somatotherapy regimens
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Barriers to care (lack of telephone access)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Barriers to care (life obligations and commitments)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Prior suicide attempts
Number of subjects: 306
Study: 16820257

Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg/day bid + Sertraline 50 mg/day od
Number of subjects: 40

Group type: COMPARATOR
Intervention: Venlafaxine XR 75 mg/day od (increased to 150 mg/day od in week 2)
Number of subjects: 40
Study: 12611754

Group type: EXPERIMENTAL
Intervention: 0.10 mg/day of transdermal 17beta-estradiol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10678926

Group type: EXPERIMENTAL
Intervention: High-dose vaccine (4.5 x 10(8) CFU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lower-dose vaccine (5 x 10(7) CFU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both high-dose and lower-dose vaccines
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 9685538

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 91
Study: 8290185

Group type: EXPERIMENTAL
Intervention: 30-minute incremental oxytocin infusion regimen
Number of subjects: 124

Group type: COMPARATOR
Intervention: 15-minute incremental oxytocin infusion regimen
Number of subjects: 124
Study: 2566779

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 4 months
Number of subjects: 22
Study: 1097222

Group type: EXPERIMENTAL
Intervention: Single oral dose of prednisone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Maintenance administration of prednisone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Single dose of prednisone when headaches began
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31888738

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study: 28704410

Group type: EXPERIMENTAL
Intervention: Values affirmation manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 25176389

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control (Cyclosporine)
Number of subjects: 202
Study: 23386556

Group type: EXPERIMENTAL
Intervention: Therapeutic Assessment (TA) training
Number of subjects: 24
Study: 21492377

Group type: EXPERIMENTAL
Intervention: Infusion method group (32 patients) with 300-500 mL warm normal saline infused into the bladder before IDC removal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard IDC removal group (28 patients)
Number of subjects: 60
Study: 17876505

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with multimodal behavior therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 16426470

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Meperidine 0.5 mg kg(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Meperidine
Number of subjects: 120
Study: 14557583

Group type: EXPERIMENTAL
Intervention: L-DOPA (400 mg/day)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 10848743

Group type: EXPERIMENTAL
Intervention: Amorolfine 5% solution nail lacquer + oral terbinafine for 6 weeks (AT6 group)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Amorolfine 5% solution nail lacquer + oral terbinafine for 12 weeks (AT12 group)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Terbinafine alone for 12 weeks (Control group)
Number of subjects: 147
Study: 9116614

Group type: EXPERIMENTAL
Intervention: Autologous peripheral stem cell transplantation (PSCT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PSCT
Number of subjects: 116
Study: 7907662

Group type: EXPERIMENTAL
Intervention: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 100 mg/kg, given twice weekly for 6 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 3, 10, or 30 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine) at 100 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous L-2-oxothiazolidine-4-carboxylic acid (Procysteine)
Number of subjects: 24
Study: 2640452

Group type: EXPERIMENTAL
Intervention: Furosemide (0.5 mg/kg body weight)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31092460

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression
Number of subjects: 73
Study: 28499258

Group type: EXPERIMENTAL
Intervention: Higher baseline levels of positive alcohol expectancies
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Lower baseline levels of positive alcohol expectancies (US sample)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Lower baseline levels of drinks per week (US sample)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Increase in positive alcohol expectancies over time (Swedish sample)
Number of subjects: 870
Study: 25668333

Group type: EXPERIMENTAL
Intervention: Positive sedimentation sign
Number of subjects: 115
Study: 24045669

Group type: EXPERIMENTAL
Intervention: TSU-68 plus S-1/CDDP
Number of subjects: 93

Group type: COMPARATOR
Intervention: S-1/CDDP
Number of subjects: 93
Study: 21456072

Group type: EXPERIMENTAL
Intervention: Total androgen blockade (TAB)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Polyestradiol phosphate (PEP)
Number of subjects: 131
Study: 18155050

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine 5 mg per mL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intrathecal ropivacaine 10 mg per mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison of bupivacaine and ropivacaine
Number of subjects: 40
Study: 17184102

Group type: EXPERIMENTAL
Intervention: Esterified conjugated estrogens (ECE) 0.156 mg/day (ultra low‐dose) (n = 18)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Esterified conjugated estrogens (ECE) 0.312 mg/day (low‐dose) (n = 17)
Number of subjects: 35
Study: 12900696

Group type: EXPERIMENTAL
Intervention: Baseball velocity of 26.8 m.s(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseball velocity of 33.5 m.s(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Attention conditions (full attention and attention splitting)
Number of subjects: 100
Study: 10691814

Group type: EXPERIMENTAL
Intervention: Hemi-KUB X-rays
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard radiological procedures (control group)
Number of subjects: 2
Study: 9093637

Group type: EXPERIMENTAL
Intervention: 1 mg/kg DEC
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 6 mg/kg DEC
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 12 mg/kg DEC
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DEC (various doses)
Number of subjects: 31
Study: 1552649

Group type: EXPERIMENTAL
Intervention: Stopping smoking (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Continuing smoking (Group B)
Number of subjects: 90
Study: 2866071

Group type: EXPERIMENTAL
Intervention: Continuous sulfasalazine
Number of subjects: 28

Group type: COMPARATOR
Intervention: On-demand sulfasalazine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rectal biopsies
Number of subjects: 28